References
- Bang Y, Van Cutsem E, Feyereislova A, et al (2010). ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
- Citri A, Kochupurakkal BS, Yarden Y (2004). The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle, 3, 51-60.
- Fessler SP, Wotkowicz MT, Mahanta SK, et al (2009). MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat, 118, 113-24. https://doi.org/10.1007/s10549-009-0412-3
- Gerlinger M, Rowan AJ, Horswell S, et al (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 366, 883-92. https://doi.org/10.1056/NEJMoa1113205
- Hikita ST, Kosik KS, Clegg DO, et al (2008). MUC1* mediates the growth of human pluripotent stem cells. PLoS One, 3, e3312. https://doi.org/10.1371/journal.pone.0003312
- Lang SA, Klein D, Moser C, et al (2007). Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther, 6, 1123-32. https://doi.org/10.1158/1535-7163.MCT-06-0628
- Lapointe J, Li C, Higgins JP, et al (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A, 101, 811. https://doi.org/10.1073/pnas.0304146101
- L'Esperance S, Popa I, Bachvarova M, et al (2006). Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol, 29, 5-24.
- Mahanta S, Fessler SP, Park J, et al (2008). A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One, 3, e2054. https://doi.org/10.1371/journal.pone.0002054
- Nahta R, Esteva FJ (2007). Trastuzumab: triumphs and tribulations. Oncogene, 26, 3637-43. https://doi.org/10.1038/sj.onc.1210379
- Price, Schiavi SA, Jepson S, Li P, et al (2002). Rat Muc4 (sialomucin complex) reduces binding of anti. ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer, 99, 783-791. https://doi.org/10.1002/ijc.10410
- Raina D, Kharbanda S, Kufe D (2004). The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem, 279, 20607-12. https://doi.org/10.1074/jbc.M310538200
- Ren J, Agata N, Chen D, et al (2004). Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 5, 163-75. https://doi.org/10.1016/S1535-6108(04)00020-0
- Siragusa M, Zerilli M, Iovino F, et al (2007). MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res, 67, 5522. https://doi.org/10.1158/0008-5472.CAN-06-4197
- Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84. https://doi.org/10.1093/annonc/mdl475
- Velho S, Oliveira C, Ferreira A, et al (2005). The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer, 41, 1649-54. https://doi.org/10.1016/j.ejca.2005.04.022
- Vogel CL, Cobleigh MA, Tripathy D, et al (2001). Firstline Herceptin monotherapy in metastatic breast cancer. Oncology, 2, 37-42.
- Yang J, Luo H, Li Y, et al (2012). Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys, 62, 221-28. https://doi.org/10.1007/s12013-011-9286-1
- Yin L, Li Y, Ren J, et al (2003). Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem, 278, 35458-64. https://doi.org/10.1074/jbc.M301987200
Cited by
- RNA Interference: a Promising Therapy for Gastric Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5509
- Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases vol.32, pp.8, 2015, https://doi.org/10.1007/s10719-015-9606-6
- Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells vol.49, pp.2, 2016, https://doi.org/10.3892/ijo.2016.3534
- MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target vol.36, pp.5, 2017, https://doi.org/10.1038/onc.2016.241
- Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers pp.1573-7233, 2019, https://doi.org/10.1007/s10555-019-09781-w